echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The new drug of hyperkalemia - AstraZeneca's zirconium cyclosilicate sodium powder is urgently needed in clinical practice!

    The new drug of hyperkalemia - AstraZeneca's zirconium cyclosilicate sodium powder is urgently needed in clinical practice!

    • Last Update: 2020-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 31, AstraZeneca's zs-9 powder was approved by the State Food and Drug Administration for marketing to treat adult hyperkalemia Hyperkalemia is a common complication of chronic kidney disease If not treated in time, it can lead to arrhythmia or even sudden death It is estimated that there are about 2 million patients with end-stage renal disease in the world Although undergoing dialysis treatment, most patients still have high blood potassium level At present, the commonly used drugs in clinical treatment are patiromer sorbitol calcium and sodium polystyrene sulfonate / calcium, but only sodium polystyrene sulfonate / calcium has been approved for marketing in China, and the clinical needs have not been met This product is hyperkalemia drug, trade name lokelma, is a highly selective oral potassium remover Originally developed by zspharma, AstraZeneca acquired the development right of this potentially heavy drug after acquiring zspharma for us $2.7 billion in November 2015 Lokelma was approved by the European Commission in March 2018 and the US FDA in May 2018 for the treatment of adult patients with hyperkalemia In May this year, sodium zirconate cyclosilicate powder was included in the list of the second batch of clinically urgent overseas new drugs The listing application of AstraZeneca was accepted by CDE on July 10, 2019 Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.